AR108552A1 - Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos - Google Patents
Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticosInfo
- Publication number
- AR108552A1 AR108552A1 ARP170101381A ARP170101381A AR108552A1 AR 108552 A1 AR108552 A1 AR 108552A1 AR P170101381 A ARP170101381 A AR P170101381A AR P170101381 A ARP170101381 A AR P170101381A AR 108552 A1 AR108552 A1 AR 108552A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapeutic agent
- value
- cells
- rate
- il2r
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 18
- 229940124597 therapeutic agent Drugs 0.000 title abstract 18
- 238000000034 method Methods 0.000 title abstract 4
- 239000000463 material Substances 0.000 title 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 6
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 5
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Theoretical Computer Science (AREA)
- Computing Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
En particular, se refiere a regímenes de administración para agentes terapéuticos capaces de reconocer el receptor de IL-2, preferentemente agentes terapéuticos basados en interleuquina 2 (IL-2). Los métodos permiten determinar regímenes generales de administración para agentes terapéuticos con diana en IL-2R, aunque también regímenes de administración específicamente adaptados para individuos bajo tratamiento con agentes terapéuticos con diana en IL-2R. Reivindicación 1: Método para la determinación de un régimen de administración óptimo para un agente terapéutico, comprendiendo dicho método: a) simular un modelo utilizando datos obtenidos de uno o más individuos en uno o más puntos temporales tras la administración de una dosis del agente terapéutico, en el que los datos incluyen datos FC referidos a la cantidad de agente terapéutico no unido, en el que el modelo es: en la que [Ab]ₗⁱᵇʳₑ es la concentración de agente terapéutico no unido en el plasma; [IL2R]ₗⁱᵇʳₑ es la concentración de células inmunológicas no unidas que expresan receptor de IL-2 en la sangre y dada por kⁱₙ / kₒᵘₜ. u opcionalmente obtenida a partir de datos FC; [Complejo] es la concentración del complejo entre el agente terapéutico y las células inmunológicas que expresan receptor de IL-2 (células IL2R⁺); kₑₗⁱₘ. es una tasa de eliminación constante del agente terapéutico del plasma y presenta un valor de entre 0.02 y 0.04 hora⁻¹; kₒₙ es una tasa de asociación del complejo entre el agente terapéutico y las células inmunológicas que expresan receptor de IL-2 y presenta un valor de entre 0.26 y 4.5 mM.⁻¹h⁻¹; kₒᶠᶠ es la tasa de disociación del complejo entre el agente terapéutico y las células inmunológicas que expresan receptor de IL-2 y presenta un valor de entre 0.0035 y 0.02 h⁻¹; kⁱₙ es la tasa de flujo de entrada constante de células IL2R⁺ en el plasma y presenta un valor de entre 0.0006 y 0.0144 mM.h⁻¹; kₒᵘₜ es la tasa de descomposición natural de las células IL2R⁺ en el plasma y presenta un valor de entre 0.0018 y 0.069 h⁻¹; kⁱₙₜ es la tasa de internalización del agente terapéutico y presenta un valor de entre 0.0066 y 0.023 h⁻¹; y h es la tasa constante de expansión de las células IL2R⁺ en el plasma como resultado de la unión (internalización) del agente terapéutico y presenta un valor de entre 1.02 y 3.31, b) proporciona un régimen de administración óptimo basado en el incremento de agente terapéutico necesario para compensar la reducción de agente terapéutico libre, en el que agente terapéutico es un compuesto que es capaz de reconocer IL2R.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171263 | 2016-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108552A1 true AR108552A1 (es) | 2018-08-29 |
Family
ID=56096950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101381A AR108552A1 (es) | 2016-05-25 | 2017-05-23 | Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12094586B2 (es) |
| EP (1) | EP3465494A1 (es) |
| JP (1) | JP6943885B2 (es) |
| KR (1) | KR20190015345A (es) |
| CN (1) | CN109478421B (es) |
| AR (1) | AR108552A1 (es) |
| AU (1) | AU2017269764A1 (es) |
| BR (1) | BR112018074152A8 (es) |
| CA (1) | CA3025050A1 (es) |
| IL (1) | IL263073A (es) |
| MX (1) | MX2018014432A (es) |
| WO (1) | WO2017202786A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| JP2022553370A (ja) * | 2019-10-25 | 2022-12-22 | ネオルーキン セラピューティクス，インコーポレイティド | Ｉｌ－２受容体作動薬の投与方法 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10245508A1 (de) * | 2002-09-27 | 2004-04-08 | Mcs Micro Carrier Systems Gmbh | Medikament-Dosimeter-Kombipackung |
| US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US20070098685A1 (en) * | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| CA2911569C (en) * | 2005-11-29 | 2019-11-26 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| DE102006028232A1 (de) * | 2006-06-20 | 2007-12-27 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis |
| EP3082848B1 (en) * | 2013-12-06 | 2023-10-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| JP2017528433A (ja) * | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| EP3482766B1 (en) * | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
-
2017
- 2017-05-22 EP EP17727144.2A patent/EP3465494A1/en active Pending
- 2017-05-22 CN CN201780045896.7A patent/CN109478421B/zh active Active
- 2017-05-22 JP JP2018561513A patent/JP6943885B2/ja active Active
- 2017-05-22 BR BR112018074152A patent/BR112018074152A8/pt not_active IP Right Cessation
- 2017-05-22 MX MX2018014432A patent/MX2018014432A/es unknown
- 2017-05-22 WO PCT/EP2017/062302 patent/WO2017202786A1/en not_active Ceased
- 2017-05-22 AU AU2017269764A patent/AU2017269764A1/en not_active Abandoned
- 2017-05-22 CA CA3025050A patent/CA3025050A1/en not_active Abandoned
- 2017-05-22 KR KR1020187037309A patent/KR20190015345A/ko not_active Abandoned
- 2017-05-23 AR ARP170101381A patent/AR108552A1/es unknown
-
2018
- 2018-11-18 IL IL263073A patent/IL263073A/en unknown
- 2018-11-20 US US16/196,883 patent/US12094586B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL263073A (en) | 2019-03-31 |
| MX2018014432A (es) | 2019-04-01 |
| JP2019530907A (ja) | 2019-10-24 |
| US12094586B2 (en) | 2024-09-17 |
| CA3025050A1 (en) | 2017-11-30 |
| JP6943885B2 (ja) | 2021-10-06 |
| US20190361018A1 (en) | 2019-11-28 |
| EP3465494A1 (en) | 2019-04-10 |
| AU2017269764A1 (en) | 2018-12-13 |
| CN109478421A (zh) | 2019-03-15 |
| BR112018074152A8 (pt) | 2023-01-31 |
| WO2017202786A1 (en) | 2017-11-30 |
| KR20190015345A (ko) | 2019-02-13 |
| CN109478421B (zh) | 2024-07-09 |
| BR112018074152A2 (pt) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108552A1 (es) | Materiales y métodos para determinar los regímenes óptimos de administración para agentes terapéuticos | |
| CO2019010698A2 (es) | Vacunas de peptidos | |
| RU2017111300A (ru) | Центральные т-клетки памяти для адоптивной т-клеточной терапии | |
| CL2018002763A1 (es) | Moléculas de unión a bcma y métodos de uso de las mismas. | |
| SA522431672B1 (ar) | Cd3 أجسام مضادة للارتباط بـ | |
| MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
| CL2018003348A1 (es) | Péptidos y combinación de péptidos y andamiajes novedosos para su uso en inmunoterapia contra carninoma de células renales (rcc) y otros canceres. (divisional solicitud 201702448) | |
| PH12018502250A1 (en) | Cancer immunotherapy by immune activation for immune modulation via globo series antigens | |
| CY1122155T1 (el) | Συζευγμενες ενωσεις που περιλαμβανουν αντισωματα τροποποιημενης κυστεϊνης | |
| EA202190295A1 (ru) | Т-клетки с химерным антигенным рецептором, происходящие от плюрипотентных стволовых клеток, полученных посредством иммуноинженерии | |
| EP4360639A3 (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| MX2019008413A (es) | Celulas pluripotentes inmunodiseñadas. | |
| MX2020014296A (es) | Variantes de interleucina-2 y sus métodos de uso. | |
| ECSP21052194A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
| AR104296A1 (es) | Infusión arterial hepática de células car-t | |
| MX2023001851A (es) | Neoantigenos ras y usos de los mismos. | |
| WO2008094178A3 (en) | Models for vaccine assessment | |
| MX2016010998A (es) | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. | |
| EP4477270A3 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| WO2014008206A3 (en) | DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E | |
| CL2021000532A1 (es) | Vacunas peptídicas | |
| EA201892443A1 (ru) | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови | |
| BR112023024434A2 (pt) | Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas | |
| WO2019113375A3 (en) | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells | |
| WO2020146434A3 (en) | Ex vivo activated t-lymphocytic compositions and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |